Eligible Part D beneficiaries pay a flat $50 for certain weight-management GLP-1s regardless of dose, under a pilot running to the end of 2027.
The Medicare GLP-1 Bridge, agreed between Eli Lilly and the US government, began dispensing on 1 July 2026. Eligible Part D beneficiaries pay no more than $50 per month for covered weight-management products, flat across doses, under a pilot scheduled to run through 31 December 2027.
For tirzepatide, only the Zepbound KwikPen is included. Mounjaro is not, because it is approved for type 2 diabetes rather than weight management. Wegovy pens and tablets and the oral agent Foundayo are also listed as eligible.
This is the single largest coverage change in the category since Part D's statutory exclusion of weight-loss drugs, and it inverts the usual advice for anyone on Medicare: the brand pathway may now be cheaper than any compounded route, which has not been true before.
Eligibility rules matter more than the headline. Check your specific plan rather than assuming, and note that manufacturer savings cards remain unavailable to federal programme participants — the Bridge is a different mechanism, not a copay card.
Sources
- Lilly and US government agreement on obesity medicine access
- Medicare Part D plan documentation
Dated 2026-07-01. If this item is out of date or wrong, tell us through contact and the change is logged in corrections.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.